Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | FGB | P02675 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3181168 | 0.95 | APP (0.42) | APPNSD2FGBMMP14CYP2C19 | |
| SCHEMBL11241170 | 0.93 | APP (0.41) | APPNSD2FGBMMP14CYP2C19 | |
| SCHEMBL917868 | 0.91 | APP (0.42) | APPCYP2C19PTGS1PDE4ALMNA | |
| SCHEMBL918086 | 0.91 | APP (0.42) | APPCYP2C19PTGS1PDE4ALMNA | |
| SCHEMBL918312 | 0.90 | APP (0.50) | APPCYP2C19PTGS1PDE4ALMNA | |
| SCHEMBL917692 | 0.88 | APP (0.41) | APPCYP2C19PTGS1PDE4ALMNA | |
| SCHEMBL918521 | 0.88 | APP (0.41) | APPCYP2C19PTGS1PDE4ALMNA | |
| SCHEMBL28285093 | 0.88 | APP (0.41) | APPCYP2C19PTGS1PDE4ALMNA | |
| SCHEMBL2121438 | 0.87 | APP (0.48) | APPCYP2C19PTGS1PDE4ALMNA | |
| Diethanolamine SCHEMBL14742047 | 0.85 | LMNA (0.38) | APPNSD2FGBMMP14CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466189-B2 | Absorption cycle apparatus and related method | GENERAL ELECTRIC COMPANY (US) | 2022-10-11 | — | — | US | claimed |
| US-20200172782-A1 | ABSORPTION CYCLE APPARATUS AND RELATED METHOD | GE INFRASTRUCTURE TECHNOLOGY LLC | 2020-06-04 | — | — | US | claimed |
| WO-2018186859-A1 | ABSORPTION CYCLE APPARATUS AND RELATED METHOD | GENERAL ELECTRIC COMPANY (US) | 2018-10-11 | — | — | WO | claimed |
| US-20110281951-A1 | Compositions and methods for treating amyloidosis | BHI LIMITED PARTNERSHIP (CA) | 2011-11-17 | — | — | US | claimed |
| JP-4726304-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| EP-1276483-B1 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | BELLUS HEALTH INT LTD (CH) | 2009-09-02 | — | — | EP | claimed |
| US-20090099100-A1 | Compositions and methods for treating amyloidosis | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2009-04-16 | — | — | US | claimed |
| EP-1609467-A1 | Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions | Neurochem (International) Limited (CH) | 2005-12-28 | — | — | EP | claimed |
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-03-03 | — | — | US | claimed |
| JP-2003517458-A | — | — | 2003-05-27 | — | — | JP | claimed |
| EP-1303311-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | Neurochem, Inc. (CA) | 2003-04-23 | — | — | EP | claimed |
| EP-1276483-A2 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2003-01-22 | — | — | EP | claimed |
| US-20020193395-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | QUEEN'S UNIVERSITY | 2002-12-19 | — | — | US | claimed |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (GI) | 2002-08-22 | — | — | US | claimed |
| WO-2002007781-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | NEUROCHEM INC. (CA) | 2002-01-31 | — | — | WO | claimed |
| EP-1100487-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | Neurochem, Inc. (CA) | 2001-05-23 | — | — | EP | claimed |
| WO-2000064420-A2 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-11-02 | — | — | WO | claimed |
| WO-2000006133-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | NEUROCHEM, INC. (CA) | 2000-02-10 | — | — | WO | claimed |
| CN-115521998-B | Triazine type chromium-free tanning agent and preparation method and application thereof | 南京工业大学 | 2024-01-02 | — | — | CN | disclosed |
| US-4029638-A | YARNS, SULFONAMIDE GROUPS | AKZONA (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099100-A1 | Compositions and methods for treating amyloidosis | TTR, SNCA, ARSA | APP 5/4885NSD2 2616/4885FGB 857/4885 |
| US-20110281951-A1 | Compositions and methods for treating amyloidosis | TTR, SNCA, ARSA | APP 5/4885NSD2 2616/4885FGB 857/4885 |
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | APP 1/4885NSD2 4741/4885FGB 1402/4885 |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | APP 1/4885NSD2 4741/4885FGB 1402/4885 |
| US-20020193395-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | APP 4399/4885NSD2 4011/4885FGB 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.